Compare MYSZ & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | ENSC |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2M | 7.6M |
| IPO Year | 2017 | 2017 |
| Metric | MYSZ | ENSC |
|---|---|---|
| Price | $1.69 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 675.3K | 457.2K |
| Earning Date | 04-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.40 | ★ 65.24 |
| EPS | N/A | ★ N/A |
| Revenue | $142,000.00 | ★ $5,066,650.00 |
| Revenue This Year | $41.64 | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 125.40 | N/A |
| 52 Week Low | $0.33 | $0.23 |
| 52 Week High | $4.28 | $2.75 |
| Indicator | MYSZ | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 47.76 |
| Support Level | $0.47 | $0.40 |
| Resistance Level | $2.60 | $0.44 |
| Average True Range (ATR) | 0.24 | 0.03 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 3.48 | 10.89 |
My Size Inc is a fashion technology company operating an integrated portfolio of businesses designed to address the pressing challenges facing fashion brands and retailers today - size and fit accuracy, excess inventory management, circular economy solutions, and international market distribution. The company, through its subsidaries provide end-to-end support across the fashion value chain; delivers AI-driven size and fit solutions for fashion e-commerce companies. The firm has the following four segments: (i) Fashion e-commerce platform, (ii) SaaS solutions, (iii) resale platform for apparel, and (iv) wholesaling of footwear. The company generates the majority of its revenue from the fashion e-commerce platform segment.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.